US GLP-1 provider price records · 2026-08-11
Every GLP-1 program in one verifiable ledger.
We track 41 US telehealth programs selling tirzepatide and semaglutide — compounded and brand — and normalize every one to the same basis: medication plus every mandatory fee, at the maintenance dose, with a capture date and a source on each figure. The cheapest program, the true annual cost, and the fine print live on one page each.
Current record — computed from the dataset, 2026-08-11
- Lowest tirzepatide, month to monthNexLife · $169/mooperator-stated · 2026-08-11
- Lowest tirzepatide, 12-month all-inTrimi · $1,500/yr$125/mo equivalent · prepaid term
- Lowest FDA-approved tirzepatideLillyDirect (Zepbound) · $449/moverified · 2026-08-11
- Lowest semaglutide, month to monthbmiMD · $129/moreported · 2026-07-14
- Lowest semaglutide, 12-month all-inbmiMD · $1,188/yr$99/mo equivalent · prepaid term
- Lowest FDA-approved semaglutideNovoCare Pharmacy (Wegovy) · $349/moverified · 2026-08-11
- Best insurance navigationRo (Ro Body)concierge PA/appeals; $25 copay possible with coverage
Every line above is recomputed at build time from the normalized database. Labels change when the numbers do — see the methodology for the basis and the corrections log for changes.
Why another comparison site exists
Most "cheapest GLP-1" lists fail the same way: they compare an advertised starter price against a competitor's maintenance price, ignore membership fees, skip half the market, and never date their numbers. The result is a ranking that's wrong the day it publishes and unverifiable forever after.
This site is built the opposite way. First comes a normalized database — one row per program, one basis for every row, a capture date and source URL on every figure, and an explicit verification status (verified, provider-stated, operator-stated, reported, or unrankable). Rankings are then computed from that table at build time. When a provider we have a commercial relationship with wins a category, it wins on arithmetic anyone can re-run from the downloadable dataset; when it loses one — as happens on this very homepage — the loss publishes too. That's the whole editorial theory, and it's spelled out in the methodology and ownership disclosure.
The market, in one honest paragraph each
Tirzepatide (60% of what people search)
Compounded tirzepatide programs that publish a rankable maintenance price currently run from $169 a month (NexLife, promotional lock-in rate, operator-stated) up to $597 (LifeMD, with its $149 program fee inside the figure), with the market's median in the high-$200s. The FDA-approved floor is LillyDirect's Zepbound single-dose vials at $299 for the 2.5 mg starter and $449 for every dose from 7.5 to 15 mg — provided each refill lands inside the 45-day window. A start-price-only listing like Fifty 410's $133 cannot be ranked because no maintenance figure exists. Full tirzepatide ranking →
Semaglutide
Rankable compounded semaglutide runs from $129 a month (bmiMD) through the $150–$200 core of the market to $348 at the top. On a full year, bmiMD's twelve-month plan works out to $99 a month — currently the lowest annualized figure we hold. The FDA-approved benchmark is NovoCare's Wegovy pen at $349 across standard doses ($399 for the 7.2 mg HD pen), with a $199 introductory price on the first two starter fills and oral Wegovy tablets from $149. Full ranking →
Start from what you actually need
Lowest possible cost
Ranked by all-in monthly and true 12-month totals, with promo rates labeled.
Using insurance
Concierge prior-auth support and brand pathways that can land at a $25 copay.
FDA-approved only
LillyDirect and NovoCare direct pricing, plus the platforms that resell them.
Head-to-heads people actually run
Sixty-six computed comparisons, each built from the same rows in the database: NexLife vs Mochi, NexLife vs OrderlyMeds, NexLife vs Ro, Mochi vs OrderlyMeds, Hims vs Ro, LillyDirect vs NovoCare — see the full index.
Questions people ask
What is the cheapest GLP-1 medication online right now?
On the records this site holds today, the cheapest rankable compounded tirzepatide is NexLife at $169 a month on a labeled promotional lock-in rate ($139 a month on its twelve-month plan; standard rate $215), and the cheapest rankable compounded semaglutide month-to-month is bmiMD at $129 a month (flat at every dose, reported from July 2026 first-party captures), with bmiMD, HealthRX, and Trimi all reaching $99 a month on twelve-month equivalent plans — the lowest annualized figures in the dataset. The FDA-approved floors are LillyDirect's Zepbound vials at $299–$449 by dose and NovoCare's Wegovy pen at $349. Every figure carries a capture date and a verification status on the pricing page.
Is compounded tirzepatide legal in 2026?
It occupies a narrow, contested lane. The FDA removed tirzepatide from the drug shortage list in December 2024 and semaglutide in February 2025, which ended the shortage-era permission to compound copies of the approved products. Traditional 503A pharmacies may still compound for an individual patient when a prescriber documents a clinical need the approved product can't meet, and part of the market operates on that basis while Eli Lilly's litigation against compounders and telehealth platforms continues. Compounded products are never FDA-approved. Our tirzepatide guide covers the full picture.
Why do your prices differ from what providers advertise?
Because we normalize. Providers advertise the friendliest number they have — a starter dose, a first-month promotion, or a medication price with the membership left out. Our figures are all-in (medication plus every mandatory recurring fee) at the maintenance dose, which is the number you actually pay for most of the year. Both the advertised and normalized figures live in the database so you can see the gap.
How do I know these rankings aren't pay-to-play?
Priced rankings on this site are computed from the dataset at build time — the code takes the minimum of a column; no human assigns winners. Our commercial relationships are stated in the ownership disclosure, providers a reader can see losing categories on our own homepage, and the full dataset downloads under CC BY 4.0 so anyone can re-run the math.